The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung DiseaseSep 9, 2014

Updated second-line drug responses of multidrug-resistant tuberculosis strains from Thailand

PubMed ↗DOI ↗

Updated Apr 5, 2026

Abstract

Of 1447 multidrug-resistant tuberculosis strains tested, 99% were susceptible to linezolid.

A total of 58 extensively drug-resistant tuberculosis strains were included in the analysis.
Susceptibility rates for the tested drugs were 93-94% for aminoglycosides and 85-98% for fluoroquinolones.
Seventy-eight percent of the strains showed susceptibility to ethionamide (ETH).
Eighty-five percent of the strains were susceptible to para-aminosalicylic acid (PAS).

Simplified

The increasing incidence of multidrug-resistant tuberculosis (MDR-TB) and the emergence of extensively drug-resistant tuberculosis (XDR-TB) globally hamper the successful treatment and effective control of TB. Information on second-line drug susceptibility, which is of utmost importance for patient care, is still limited. This study demonstrates the susceptibilities of 1447 strains of MDR-TB, including 58 XDR-TB strains, isolated from Siriraj Hospital, Bangkok, Thailand, to aminoglycosides, fluoroquinolones, ethionamide (ETH), para-aminosalicylic acid (PAS) and linezolid. Results revealed that 93-94% of the MDR-TB strains were susceptible to aminoglycosides, 85-98% to fluoroquinolones, 78% to ETH, 85% to PAS and 99% to linezolid.

Full Text

Full text is available at the source.

View Full Text ↗

Abstract

Full Text

Related papers

What Lands in Your Inbox Each Week: